Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003835 · ClinicalTrials.gov registry record · Phase 3

Combination Chemotherapy in Treating Patients With Stage III Colon Cancer

A Phase 3 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 3
Development phase
1,260
Enrollment target

NCT00003835: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).

NCT00003835 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,260 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003835, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 3
Development phase
1,260 participants
Enrollment target

Study Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon cancer. Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without irinotecan in treating patients who have undergone surgery for stage III colon cancer.

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG fluorouracil
  • DRUG leucovorin calcium
  • DRUG irinotecan hydrochloride

Trial Details

FieldValue
Enrollment Target 1,260 participants
Start Date 1999-05
Phase Phase 3

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00003835

The ClinicalTrials.gov registry entry for NCT00003835 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00003835 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003835 about?

NCT00003835 is a clinical study titled "Combination Chemotherapy in Treating Patients With Stage III Colon Cancer". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon cancer. Randomized phase III trial to compare the ...

What is the current status of trial NCT00003835?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,260 participants. The study started on 1999-05.

What interventions are being tested in trial NCT00003835?

The interventions under investigation include: laboratory biomarker analysis (OTHER), fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003835?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.